Autism is a neuropsychiatric disease; one of the causes of autism is damage to neurons. L-Theanine is a bioactive compound in Camellia sinensis L.which is analogous to L-Glutamate Acid structure and its neuroprotective effect. This study aimed to analyze the binding side of L-Theanine and L-Glutamate Acid to the kainate of glutamate receptor protein to determine and the effectiveness of its inhibitor function. Toxicity analysis is also used to determine the suitability of compounds as bioactive components to be consumed orally. The method used to analyze the interaction of compounds with target proteins is reverse docking. Toxicity analysis using the Toxtree 2.6.13 and collection of information from the Human Metabolome Database. The docking shows that L-Glutamate Acid and L-Theanine have the same site in the ionotropic Glutamate receptor protein, kainate1. The residual groups of the two compounds when binding to the similar glutamate receptor protein are THR (A: 91), GLU (A: 191), and ARG (A: 96). The binding affinity of the two compounds is almost the same, namely -5.0 kcal/mol for L-Glutamate Acid and -4.9 kcal/mol for L-Theanine. This allows L-Theanine to act as an inhibitor that blocks L-Glutamate Acid from binding to glutamate receptors on prostsynap membranes. The compound docking results show that L-Theanine has four bond side residues that are the same as the same L-Glutamate Acid and binding affinity of -5.0 kcal/mol. Analysis with the principle of RO5 Lipinski is known that L-Theanine compounds have the potential if taken orally. Therefore, the C. sinensis L. potential as an anti-autism substance.

1.
P.
Curatolo
,
Y.
Ben-Ari
,
Y.
Bozzi
,
M.V.
Catania
,
E.
D’Angelo
,
L.
Mapelli
,
L.M.
Oberman
,
C.
Rosenmund
and
E.
Cherubini
,
Front. Cell. Neurosci.
8
(
309
),
1
4
(
2014
).
2.
M.
Lisik
,
Psychiatr. Pol.
48
(
4
),
689
700
(
2014
).
3.
K. M.
Heil
and
C.P.
Schaaf
,
Curr. Psychiatry Rep.
15
(
1
),
334
(
2013
).
4.
Health Grove. Autistic Spectrum Disorder in Indonesia
. (http://global-disease-burden.healthgrove.com/l/63610/Autistic-Spectrum-Disorders-in-Indonesia), (Accessed in January 2018) (
2016
)
5.
D.J.
Guerra
,
Journal of Autism Research and Treatment
2011
(
398636
),
1
16
(
2011
).
6.
R.
Dufault
,
R.
Schnoll
,
W. J.
Lukiw
,
B.
Leblanc
,
C.
Cornett
,
L.
Patrick
,
D.
Wallinga
,
S. G.
Gilbert
and
R.
Crider
,
Behav. Brain Funct.
5
(
44
),
1
15
(
2009
).
7.
N.
Sakulsak
,
Int. J. Morphol
30
(
3
),
1007
1012
(
2012
).
8.
Strunecka
, and
H.
Kruzikova
,
Cellular and Molecular Biology of Autism Spectrum Disorders
, (
Bentham E-Book
,
USA
,
2003
).
9.
T.
Kakuda
,
Biol. Pharm Bull
25
(
12
),
1513
1518
(
2002
).
10.
WebMD. Medicine for Autism
. (https://www.webmd.com/brain/autism/medications-for-autism). (Accessed in January 2018) (
2015
).
11.
Food and Drug Administration
.
FDA approves the first drug to treat irritability associated with autism, Risperdal
, (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108759.htm). (Accessed in January 2018) (
2006
).
12.
Rezapour
,
M.
Bahmani
,
O.
Afsordeh
,
R.
Rafieian
and
A.
Sheikhian
,
J. HerbMed Pharmacol.
5
(
3
),
89
91
(
2016
).
13.
Thorne.
L-Theanine
.
Altern Med Rev
10
(
2
),
136
138
(
2005
).
14.
S. P.
Kelly
,
G.
Ramirez
,
J. L.
Montesi
and
J.J.
Foxe
,
Nutr. J.
138
(
8
),
1572
1577
(
2008
).
15.
G. N.
Owen
,
H.
Parnell
,
E. A.
Brin
and
J.
Rycroft
,
Nutr. Neurosci
11
(
4
),
193
197
(
2008
).
16.
T.
Giesbrecht
,
J. A.
Rycroft
,
M. J.
Rowson
and
E. A.
De Bruin
,
Nutr. Neurosci
13
(
6
),
283
289
(
2010
).
17.
K.
Kimura
,
M.
Ozeki
,
L. R.
Juneja
and
H.
Ohira
,
Biol. Psychol.
74
(
2007
):
39
45
(
2006
).
18.
Yoto
,
M.
Motoki
and
H.
Yokogashi
,
Journal of Anthropology
31
(
28
),
1
9
(
2012
).
19.
L.
Yin
,
R.
Zheng
,
T. S.
Chen
and
T.
Lu
,
BMC. Complem. Altern. M.
15
(
41
),
1
17
(
2011
).
20.
K. T.
Schomburg
and
M.
Rarey
,
Future Med. Chem.
6
(
18
),
1987
1989
(
2014
).
21.
C.
Bortolotto
,
P.
Delany
,
V.
Smolder
,
M.B.
Hos
,
O.
Fantakes
,
L.B.
Omstein
and Collingride,
Letter to Nature
402
(
1
),
291
301
(
1999
).
22.
D.
Maulina
,
M.
Amin
,
S.R.
Lestari
and
M.
Aziz
,
JBiopest
11
(
2
):
89
97
(
2018a
).
23.
D.
Maulina
,
M.
Amin
,
S.R.
Lestari
and
M.
Aziz
,
J. Biol. Res.
23
,
2
(
2018b
).
24.
M.
Amin
,
K.S.
Putra
,
I. F.
Amin
,
N.
Earlia
,
D.
Maulina
,
B.
Lukiati
and
U.
Lestari
,
Biology, Medicine, & Natural Product Chemistry
7
(
1
),
27
31
(
2018
).
25.
Pangastuti
,
I. F.
Amin
,
A.
Zhilalikbar
and
M.
Amin
,
Jurnal Teknologi (Sciences & Engineering)
78
(
5
),
315
318
(
2016
).
26.
Kim
,
S.
,
Thiessen
,
P. A.
,
Bolto
and
E. E.
Chen
,
J. Nucleic Acid Res.
44
(
1
),
202
213
(
2015
).
27.
Wu
,
C. H.
,
Apweiler
,
R.
,
Bairoch
,
A.
,
Natale
,
D. A.
,
Barker
and
W.
Boeckman
,
Nucleic Acids Res.
43
(
1
):
187
191
(
2006
).
28.
H. M.
Berman
,
K.
Henrick
and Nakamura,
Nat. Struct. Biol.
10
(
12
),
980
(
2003
).
29.
D.S.
Wishart
,
Y.D.
Feunang
,
A.
Marcu
,
A.C.
Guo
,
K.
Liang
,
R.
Vázquez-Fresno
,
T.
Sajed
,
D.
Johnson
,
C.
Li
,
N.
Karu
and
Z.
Sayeeda
,
Nucleic acids res.
46
(
1
),
608
617
(
2017
).
30.
Lipinski
,
Drug Discov. Today Technol.
1
(
4
),
337
341
(
2004
).
31.
S. K.
Bhal
, Lipophilicity Descriptors: Understanding When to Use LogP & LogD.
Application Note
. (
Advanced Chemistry Development, Inc
.
Toronto, Canada
,
2007
),
27
.
32.
D.F.
Veber
,
S.R.
Johnson
,
H.Y.
Cheng
,
B.R.
Smith
,
K.W.
Ward
and
K.D.
Kopple
,
J. Med. Chem.
45
(
1
),
2615
2623
(
2002
).
This content is only available via PDF.
You do not currently have access to this content.